Abstract
Academic institutions are a well-established source of pharmaceutical innovation. However, the researchers behind these discoveries are rarely responsible for successful translation of their findings to the market. It is hypothesized that by enhancing their understanding and knowledge of the regulatory requirements associated with drug development, the speed of innovation to market would be increased, while simultaneously decreasing technology transfer issues that arise as commercially focused projects move from academia to industry. The usefulness of an associated regulatory readiness tool to guide researchers involved in commercially focused projects will also be investigated.
Recommended Citation
Harris, Elaine and O'Reilly, Eimear
(2020)
"From Idea to Therapeutic: Is There a Role for Developing a Regulatory Pathway Tool for Early Stage Research?,"
Level 3:
Vol. 15:
Iss.
2, Article 7.
doi:https://doi.org/10.21427/jp6q-7t23
Available at:
https://arrow.tudublin.ie/level3/vol15/iss2/7
DOI
https://doi.org/10.21427/jp6q-7t23
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 International License.